Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
ClinicalTrials.gov study NCT03499899. IPD Sharing: YES. Countries: 17. Publications: 0.
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01815242. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT05382299. IPD Sharing: NO. Countries: 30. Publications: 1.
Data for: Link between glucose metabolism and EMT drives triple negative breast cancer migratory heterogeneity
Open the record for dataset details and reuse information.
HCC38 and MDA-MB-231 Triple-Negative Breast Cancer time lapses at different densities
<p>Supporting data set for Burger et al. Density-dependent migration characteristics of cancer cells driven by pseudopod coordination. In preparation.</p>
Triple-negative breast cancer and Natural killer cells
SciDraw 6 Drawing Upload
Triple-negative breast cancer and Natural killer cells
SciDraw 6 Drawing Upload
Dataset associated with publication of Budzyń et al. "The significance of monocyte CCR2_CCL2 axis in triple negative breast cancer"
<p>Row data</p>
Spatial profile of tumor microenvironment in PD-L1-negative and PD-L1-positive triple negative breast cancer
<p><strong>Supplementary Materials</strong></p>
Spatial Transcriptomic Experiment of Triple-Negative Breast Cancer PDX Model PIM001-P model treatment naive sample
<p>Spatial Transcriptomic Experiment of Triple-Negative Breast Cancer PDX Model PIM001-P model treatment naive sample</p> <p>10X Genomics Visium platform. </p> <p><strong>Library Preparation and Sequencing of PIM001P</strong></p> <p>Tissue sections of 10µm thickness were mounted onto the capture areas of the Visium Spatial Gene Expression slide and stained using hematoxylin and eosin. Tissue sections were permeabilized on a thermocycler for 24 minutes, as determined by the Tissue Optimization step. Poly-adenlyated mRNA is released and captured by surface-bound primers within each capture area. Reverse transcription, template switching, extension, and second strand synthesis are performed on the slide. Full-length, spatially barcoded cDNA transcripts are then denatured from the slide and amplified via PCR prior to library construction. Approximately 110 to 375 ng of amplified cDNA was carried forward into library construction. During library construction, cDNA is enzymatically fragmented to target amplicon size then undergoes end repair, A-tailing, adapter ligation, and then amplified using between 14 and 16 PCR cycles. The resulting libraries were quantitated using the Invitrogen Qubit 2.0 quantitation assay and fragment size assessed with the Agilent Bioanalyzer. A qPCR quantitation was performed on the libraries to determine the concentration of adapter ligated fragments using Applied Biosystems ViiA7 Real-Time PCR System and a KAPA Library Quant Kit (p/n KK4824). All samples were pooled equimolarly and re-quantitated by qPCR, and also re-assessed on the Bioanalyzer.</p> <p><strong>Sequencing: </strong></p> <p>150 pM of equimolarly pooled library was loaded onto the NovaSeq 6000 S4 flowcell and sequenced at the recommended 28-10-10-50 read configuration. PhiX Control v3 adapter-ligated library (Illumina p/n FC-110-3001) was spiked-in at 2% by weight to ensure balanced diversity and to monitor clustering and sequencing performance. A minimum of 300 million read pairs per sample was sequenced. FastQ file generation was executed using 10X Genomics’ Space Ranger mkfastq software.</p> <p> </p>
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT02689427. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01289353. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer
ClinicalTrials.gov study NCT03932526. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01928680. IPD Sharing: Not stated. Countries: 1. Publications: 0.
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04176848. IPD Sharing: NO. Countries: 1. Publications: 0.
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05112536. IPD Sharing: NO. Countries: 1. Publications: 0.
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03012100. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT04148911. IPD Sharing: YES. Countries: 13. Publications: 0.
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01997333. IPD Sharing: Not stated. Countries: 9. Publications: 0.
Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
ClinicalTrials.gov study NCT00817531. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.